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Background: Colorectal cancer (CRC) is one of the most common and comprehensively studied malignancies.
Hypoxic conditions during formation of CRC may support the development of more aggressive cancers. Hypoxia
inducible factor (HIF), a major player in cancerous tissue adaptation to hypoxia, is negatively regulated by the family
of prolyl hydroxylase enzymes (PHD1, PHD2, PHD3) and asparaginyl hydroxylase, called factor inhibiting HIF (FIH).
Methods: PHD1, PHD2, PHD3 and FIH gene expression was evaluated using quantitative RT-PCR and western
blotting in primary colonic adenocarcinoma and adjacent histopathologically unchanged colonic mucosa from
patients who underwent radical surgical resection of the colon (n = 90), and the same methods were used for
assessment of PHD3 gene expression in HCT116 and DLD-1 CRC cell lines. DNA methylation levels of the CpG island
in the promoter regulatory region of PHD1, PHD2, PHD3 and FIH were assessed using bisulfite DNA sequencing and
high resolution melting analysis (HRM) for patients and HRM analysis for CRC cell lines.
Results: We found significantly lower levels of PHD1, PHD2 and PHD3 transcripts (p = 0.00026; p < 0.00001;
p < 0.00001) and proteins (p = 0.004164; p = 0.0071; p < 0.00001) in primary cancerous than in histopathologically
unchanged tissues. Despite this, we did not observe statistically significant differences in FIH transcript levels
between cancerous and histopathologically unchanged colorectal tissue, but we found a significantly increased
level of FIH protein in CRC (p = 0.0169). The reduced PHD3 expression was correlated with significantly increased
DNA methylation in the CpG island of the PHD3 promoter regulatory region (p < 0.0001). We did not observe DNA
methylation in the CpG island of the PHD1, PHD2 or FIH promoter in cancerous and histopathologically unchanged
colorectal tissue. We also showed that 5-Aza-2’-deoxycytidine induced DNA demethylation leading to increased
PHD3 transcript and protein level in HCT116 cells.
Conclusion: We demonstrated that reduced PHD3 expression in cancerous tissue was accompanied by methylation of
the CpG rich region located within the first exon and intron of the PHD3 gene. The diminished expression of PHD1 and
PHD2 and elevated level of FIH protein in cancerous tissue compared to histopathologically unchanged colonic
mucosa was not associated with DNA methylation within the CpG islands of the PHD1, PHD2 and FIH genes.Background
Colorectal cancer (CRC) belongs to one of the most ex-
tensively studied types of cancers due to its high mor-
tality and severity. It is the third and second leading
cause of death from malignant disease among adults in
the US and Europe, respectively [1]. A decrease in oxy-
gen concentration is widely seen during the formation* Correspondence: arawluszko@ump.edu.pl
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reproduction in any medium, provided the orof many solid tumors, including CRC. Hypoxic regions
may occur due to poorly formed vasculature, shunting
of blood and vascular permeability [2]. Cancer cells can
adjust to this microenvironment by altering gene tran-
scription to enhance glucose uptake and angiogenesis [2].
The various adaptive responses involve multiple mecha-
nisms, of which the best-characterized is mediated
through transcriptional gene activation by the hypoxia in-
ducible factor (HIF) [3]. HIF is a heterodimeric transcrip-
tion factor assembled from an oxygen-regulated α subunit
(HIF-α) and a constitutively expressed β subunit (HIF- β)tral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic and histopathological classification
including stage, grade and tumour type of patients with
CRC
Features No. of patients
Total no. of patients 90
Gender (Female/Male) 41/49
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the nucleus, where it forms a dimer with HIF-β to
form an active transcriptional complex with a number of
cofactors [3,4]. The HIF complex binds to the promoter
hypoxia response elements (HREs) to induce the expres-
sion of target genes that regulate the cellular adaptive
response to low oxygen tension [3,4].
HIF-α is constitutively expressed in the tissue; however,
it has an extremely short half-life in normoxic conditions
[3]. The level of HIF-α protein is regulated in several
ways. The most well known is its degradation through
post-translational hydroxylation. To date, two different
oxygen-dependent hydroxylation mechanisms have been
identified. The first pathway is initiated by three prolyl hy-
droxylase domain enzymes, PHD1, PHD2 and PHD3 [3].
The second pathway involves the factor inhibiting HIF
(FIH) [5]. The PHD enzymes catalyze the hydroxylation of
two conserved proline residues in the oxygen dependent
degradation domain of the HIF-α protein. Hydroxylated
proline residues are subsequently recognized by the E3
ligase complex containing von Hippel–Lindau tumour
suppressor protein (pVHL), and targeted for degradation
by the 26S proteasome [3]. Similarly, FIH hydroxylates the
asparagine residue within the C-terminal transactivation
domain of HIF-α [5,6]. This results in the prevention of
HIF-α interaction with its coactivators. Hence, under nor-
moxic conditions, there is a dual mechanism of HIF inhib-
ition by its degradation or inactivation by PHDs and FIH
enzymes, respectively.
Recently, various studies have demonstrated inconsist-
ent data of FIH and PHD1, 2 and 3 expression changes
during CRC development [7-10]. The mechanism by
which these hydroxylases might be regulated is still not
well elucidated. Interestingly, PHDs and FIH genes possess
a CpG island within their promoter region. Similarly to
genetic mutations, hyper- or hypomethylation of gene
regulatory sequences have been shown to potentially
change the expression of cancer related genes in different
malignancies, including CRC [11]. To date, it has been
demonstrated that the promoter region of the PHD3 gene
is hypermethylated in plasma cell neoplasia, prostate, mel-
anoma and mammary gland cancer cell lines [12,13]. The
DNA methylation status of PHD1, PHD2 and FIH has
also been investigated in breast, cervical and prostate can-
cer cell lines, but the results are inconsistent [12,14,15].
These reports prompted us to study whether altered
PHD1, PHD2, PHD3 and FIH expression levels may be
correlated with the DNA methylation status of their pro-
moter regions in primary cancerous and histopathologic-
ally unchanged colorectal tissue from the same ninety
patients. We also evaluated the effect of 5-Aza-2’-deoxycy-
tidine (5-dAzaC), an inhibitor of DNA methyltransferases
(DNMTs), on the DNA methylation level of the PHD3




Rabbit polyclonal (Rp) anti-PHD1 (NB100-310), -PHD2
(NB100-137), -PHD3 (NB100-139) and -FIH (NB100-428)
antibodies (Ab) were provided by Novus Biologicals
(Cambridge, UK). Rp anti-GAPDH Ab (FL-335) and goat
anti-rabbit horseradish peroxidase (HRP)-conjugated Ab
were provided by Santa Cruz Biotechnology (Santa Cruz,
CA). 5-dAzaC was purchased from Sigma-Aldrich Co.
(St. Louis, MO).
Patient material
Primary colonic adenocarcinoma tissues were collected
between June 2009 and July 2012 from ninety patients
who underwent radical surgical resection of the colon
at the Department of General and Colorectal Surgery,
Poznań University of Medical Sciences, Poland (Table 1).
Histopathologically unchanged colonic mucosa located
at least 10–20 cm away from the cancerous lesions was
obtained from the same patients. Since ex vivo stress
may influence protein stability, one set of samples was
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at -80ºC until RNA/DNA/protein isolation [16]. An-
other set of samples was directed for histopathological
examination. Histopathological classification including
stage, grade and tumour type was performed by an ex-
perienced pathologist. No patients received preoperative
chemo- or radiotherapy. Written informed consent was
obtained from all participating individuals. The procedures
of the study were approved by the Local Ethical Commit-
tee of Poznań University of Medical Sciences.
Cell culture
DLD-1 colon cancer cells were obtained from the Ameri-
can Type Culture Collection (Rockville, MD) and HCT116
cells were kindly provided by the Department of Experi-
mental and Clinical Radiobiology, Maria Skłodowska-Curie
Cancer Center, Institute of Oncology Branch, Gliwice,
Poland. These cells were cultured in DMEM GibcoBRL
(Grand Island, NY) containing 10% heat-inactivated fetal
bovine serum (FBS) and 2 mM glutamine. To determine
the effect of 5-dAzaC on DNA methylation, transcript and
protein levels of selected genes, the HCT116 and DLD-1
cells were cultured for 24 hours in DMEM GibcoBRL
(Grand Island, NY) supplemented with 10% FBS from
Sigma-Aldrich Co. (St. Louis, MO). Cells were then
cultured under normoxic or hypoxic (1% O2) conditions
either in the absence or in the presence of 5-dAzaC at a
concentration of 1.00 or 5.00 μM for 6, 24 and 48 hours.
Hypoxic conditions were achieved using a MCO-18 M
multigas cell culture incubator, Sanyo (Wood Dale, IL),
modified to permit flushing the chamber with a humidified
mixture of 5% CO2, 94% N2. These cells were used for total
DNA, RNA isolation, RQ-PCR, western blotting, and
HRM analysis.
Reverse transcription and real-time quantitative polymerase
chain reaction (RQ-PCR) analysis
Total RNA from primary tissues of patients with CRC
and CRC cell lines was isolated according to the method
of Chomczyński and Sacchi (1987) [17]. RNA samples
were quantified and reverse-transcribed into cDNA.
RQ-PCR was carried out in a Light Cycler®480 Real-Time
PCR System, Roche Diagnostics GmbH (Mannheim,
Germany) using SYBR® Green I as detection dye. The tar-
get cDNA was quantified by the relative quantification
method using a calibrator for primary tissue or respective
controls for HCT116 and DLD-1 cells. The calibrator
was prepared as a cDNA mix from all of the patients’
samples and successive dilutions were used to create a
standard curve as described in Relative Quantification
Manual Roche Diagnostics GmbH, (Mannheim,
Germany). For amplification, 1 μl of total (20 μl) cDNA
solution was added to 9 μl of IQ™ SYBR® Green Super-
mix, Bio-Rad Laboratories Inc. (Hercules, CA) withprimers (Additional file 1). To prevent amplification of
sequences from genomic DNA contamination, primers
and/or amplicons were designed at exon/exon boundaries
and covered all gene splice variants (Additional file 1).
The quantity of PHD1, PHD2, PHD3 and FIH transcript
in each sample was standardized by the geometric mean
of two internal controls. The internal control genes were
porphobilinogen deaminase (PBGD) and human mitochon-
drial ribosomal protein L19 (hMRPL19) (Additional file 1).
They were selected from four candidate reference genes
(PBGD, hMRPL, peptidylprolyl isomerase A- PPIA,
hypoxanthine phosphoribosyltransferase 1- HPRT) based
on the results achieved in geNorm VBA applet for Micro-
soft Excel (data not shown) [18,19]. The PHD1, PHD2,
PHD3 and FIH transcript levels in the patients’ tissues
were expressed as multiplicity of cDNA concentrations
in the calibrator. In HCT116 and DLD-1 cells, tran-
script levels were presented as multiplicity of the
respective controls.Western blotting analysis
Primary tissues from patients with CRC, HCT116 and
DLD-1 cells were treated with lysis RIPA buffer and pro-
teins were resuspended in sample buffer and separated on
10% Tris-glycine gel using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Gel pro-
teins were transferred to a nitrocellulose membrane, which
was blocked with 5% milk in Tris/HCl saline/Tween buffer.
Immunodetection of bands was performed with Rp anti-
PHD1, -PHD2, -PHD3 and -FIH Ab, followed by incuba-
tion with goat anti-rabbit HRP-conjugated Ab. To ensure
equal protein loading of the lanes, the membrane was
stripped and incubated with Rp anti-GAPDH Ab (FL-335),
followed by incubation with goat anti-rabbit HRP-
conjugated Ab. Bands were revealed using SuperSignal
West Femto Chemiluminescent Substrate, Thermo Fisher
Scientific (Rockford, IL) and Biospectrum® Imaging System
500, UVP Ltd. (Upland, CA). The amounts of analyzed
proteins were presented as the protein-to-GAPDH band
optical density ratio. For HCT116 and DLD-1 cells
cultured in the absence of 5-dAzaC, the ratio of PHD3 to
GAPDH was assumed to be 1.DNA isolation and bisulfite modification
Genomic DNA was isolated using DNA Mammalian
Genomic Purification Kit purchased from Sigma-Aldrich
Co. (St. Louis, MO). 500 ng of genomic DNA was
subjected to bisulfite conversion of cytosine to uracil
according to the EZ DNA Methylation Kit™ procedure
from Zymo Research Corporation (Orange, CA). The
position of CpG islands and binding sites of transcrip-
tion factors located in the regulatory region of the
promoter was determined by online programs [20-22].
Rawluszko et al. BMC Cancer 2013, 13:526 Page 4 of 16
http://www.biomedcentral.com/1471-2407/13/526DNA methylation evaluation by bisulfite sequencing
DNA fragments containing CpG dinucleotides located in
the promoter region of the PHD1, PHD2, PHD3 and FIH
genes were amplified from the bisulfite-modified DNA
by the primer pairs (Additional file 1, Additional file 2)
complementary to the bisulfite-DNA modified sequence.
PCR amplification was performed by FastStart Taq DNA
Polymerase from Roche Diagnostic GmbH (Mannheim,
Germany). The PCR products were purified using
Agarose Gel DNA Extraction Kit, Roche Diagnostic
GmbH (Mannheim, Germany) with subsequent cloning
into pGEM-T Easy Vector System I, Promega (Madison,
WI) and transformation into TOPO10 E. coli strain cells.
Plasmid DNA isolated from five positive bacterial clones
was used for commercial sequencing of the cloned frag-
ment of DNA. The results of bisulfite sequencing were
assessed and presented using BiQ analyzer software and
Bisulfite sequencing Data Presentation and Compilation
(BDPC) web server, respectively [23,24].
DNA methylation assessment by high resolution melting
(HRM) analysis
Methylation levels of DNA fragments located within the
CpG island of the PHD1, PHD2, PHD3 and FIH genes
(Additional file 2) were determined by Real Time PCR
amplification of bisulfite treated DNA followed by HRM
profile analysis by Light Cycler®480 Real-Time PCR Sys-
tem, Roche Diagnostics GmbH (Mannheim, Germany).
For PCR amplification, 1 μl of the bisulfite treated DNA
from patients, HCT116, DLD-1 cells, or standards, and
primers (Additional file 1, Additional file 2) was added
to 19 μl of 5 X Hot FIREPol EvaGreen HRM Mix, Solis
BioDyne Co. (Tartu, Estonia). Standardized solutions of
DNA methylation percentage were prepared by mixing
methylated and non-methylated bisulfite treated DNA
from Human Methylated/Non-methylated DNA Set,
Zymo Research Corp. (Orange, CA) in different ratios.
To determine the percentage of methylation, the HRM
profiles of patient DNA PCR products were compared
with HRM profiles of standard DNA PCR product
[25,26]. HRM methylation analysis was performed using
Light Cycler®480 Gene Scanning software, Roche Diagnos-
tics GmbH (Mannheim, Germany). Each PCR amplification
and HRM profile analysis was performed in tripli-
cate. Using HRM analysis we were able to detect
heterogenous methylation with equal sensitivity (Additional
file 3). The methylation for each patient was pres-
ented as a percentage of methylation in amplified frag-
ments located in the CpG island of PHD1, PHD2,
PHD3 and FIH. Since low levels of methylation may
not demonstrate significant biological effect and we are
not able to quantify all CpG dinucleotides within the
analyzed CpG island, the percentage results were
divided into three groups: 0–1% methylation, 1–10%methylation and 10–100% methylation for statistical
analysis [27-30].Statistical analysis
The normality of the observed patient data distribution
was assessed by Shapiro-Wilk test, and unpaired, two-
tailed t-test or U Mann–Whitney test was used to compare
the mean values. The chi-square test was used to examine
significance in DNA methylation. To evaluate the associ-
ation between different ranges of DNA methylation
(0–1% methylation, 1–10% methylation and 10–100%
methylation) and the ratio of cancerous tissue PHD3
mRNA level to histopathologically unchanged PHD3
mRNA level, the non-parametric Kruskal-Wallis test was
employed. Data groups for cell lines were assessed by
ANOVA to evaluate if there was significance (P < 0.05)
between the groups. For all experimental groups, which
fulfilled the initial criterion, individual comparisons were
performed by post hoc Tukey test with the assumption of
two-tailed distribution. Statistically significant results were
indicated by p < 0.05. Statistical analysis was performed
with STATISTICA 6.0 software.Results
PHD1, PHD2, PHD3 and FIH transcript and protein levels
in primary cancerous and histopathologically unchanged
tissues from patients with CRC
To compare PHD1, PHD2, PHD3, and FIH transcript
and protein levels in cancerous and histopathologically
unchanged tissues from ninety patients with CRC
we used RQ-PCR and western blotting, respectively.
We found significantly lower levels of PHD1, PHD2
and PHD3 transcript (p = 0.00026; p < 0.00001; p < 0.00001)
and protein (p = 0.004164; p = 0.0071; p < 0.00001) in
primary cancerous than in histopathologically unchanged
tissues in ninety patients with CRC (Figure 1A, B;
Figure 2). Moreover, we observed significantly lower
levels of PHD1, PHD2, PHD3 transcript and protein in
cancerous tissue in different age groups, among the
genders, CRC localization, G2 and G3 histologic grade,
levels of Dukes scale [31], and tumour stage (Additional
file 4). There was no significant difference in the levels
of FIH transcript between primary cancerous and histo-
pathologically unchanged tissues in ninety patients with
CRC (p = 0.583) (Figure 1A). However, we observed a
statistically higher level of FIH protein in primary can-
cerous than in histopathologically unchanged tissue
(p = 0.0169) (Figure 1B, Figure 2). We also found a
significantly higher level of FIH protein in cancerous
tissue in the male patient group (p = 0.0210), and in
patients aged above 60 (p = 0.0257), with CRC localized
in the rectum (p = 0.031) and G2 histologic grade (p =
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Figure 1 PHD1, PHD2, PHD3 and FIH transcript and protein levels in primary cancerous and histopathologically unchanged tissues
from patients with CRC. A. The cancerous (●) and histopathologically unchanged tissues (○) from ninety patients with CRC were used for RNA
and protein isolation. Total RNA was reverse-transcribed, and cDNAs were investigated by RQ-PCR relative quantification analysis. The PHD1,
PHD2, PHD3 and FIH mRNA levels were corrected by the geometric mean of PBGD and hMRPL19 cDNA levels. The amounts of PHD1, PHD2,
PHD3 and FIH mRNA were expressed as the decimal logarithm of multiples of these cDNA copies in the calibrator. B. Proteins were separated
by 10% SDS-PAGE, and transferred to a membrane that was then immunoblotted with Rp anti- PHD1, - PHD2, - PHD3 and - FIH Ab and incubated
with goat anti-rabbit HRP-conjugated Ab. The membrane was then stripped and blotted with Rp anti-GAPDH Ab, followed by incubation with
goat anti-rabbit HRP-conjugated Ab. The amount of western blot-detected PHD1, PHD2, PHD3 and FIH proteins was presented as the decimal
logarithm of PHD1, PHD2, PHD3 and FIH to GAPDH band optical density ratio. The p value was evaluated by unpaired, two-tailed t-test or
U-Mann-Whitney test.
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Figure 2 Representative picture of western blot in histopathologically unchanged tissue (N) and primary cancerous tissue (C) from
patients with CRC. Immunodetection of bands was performed with Rp anti- PHD1, - PHD2, - PHD3 and - FIH Ab, followed by incubation with
goat anti-rabbit HRP-conjugated Ab. The membrane was stripped and incubated with Rp anti-GAPDH Ab, followed by incubation with goat anti-
rabbit HRP-conjugated Ab. Bands were revealed using SuperSignal West Femto Chemiluminescent Substrate, Thermo Fisher Scientific (Rockford,
IL) and Biospectrum® Imaging System 500, UVP Ltd. (Upland, CA).
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histopathologically unchanged tissues from patients
with CRC
To compare DNA methylation levels in the promoter
region of the PHD1, PHD2, PHD3, and FIH genes between
DNA samples from cancerous and histopathologically un-
changed tissues, we performed sodium bisulfite DNA se-
quencing and HRM analysis (Additional file 1, Additional
file 2). Bisulfite sequencing was used for preliminary evalu-
ation of DNA methylation in large regions of selected
CpG islands in randomly selected patients. We detected a
similar pattern of DNA methylation within all individual
clones of each patient. The DNA methylation level evalu-
ation for PHD3 revealed significant differences between
cancerous and histopathologically unchanged tissue in re-
gion chr14: 34 419 346–34 419 943 (Figure 3B, Additional
file 1, Additional file 2). However, we observed no changes
of DNA methylation within the promoter of PHD3 in re-
gion chr14: 34 419 929–34 420 563 (Figure 3A, Additional
file 1, Additional file 2). Moreover, we did not detect DNA
methylation in the regulatory region of the PHD1, PHD2
and FIH genes in cancerous and histopathologically un-
changed tissue in selected patients with CRC (Additional
file 1, Additional file 2, Additional file 5). To extend DNA
methylation studies and to confirm bisulfite sequencing
data for all analyzed genes, we employed HRM analysis
of PCR amplified bisufite treated DNA for patients.
Depending on the length of the CpG island and the ampli-
fication possibilities of bisulfite treated DNA, one to three
primer pairs was used in HRM analysis (Additional file 1,Additional file 2). In keeping with the bisulfite sequencing
data, we observed no DNA methylation within the
promoter region of the PHD1, PHD2 and FIH genes in
cancerous and histopathologically unchanged tissue from
ninety patients with CRC (Additional file 1, Additional
file 2, Additional file 6). We also detected no DNA methy-
lation for PHD3 in region chr14: 34 419 922–34 420
080 in cancerous and histopathologically unchanged tis-
sue using HRM analysis (Figure 3A, Additional file 1,
Additional file 2). However, HRM evaluation showed a
significant increase in the average DNA methylation level
in cancerous compared to histopathologically unchanged
tissue from ninety patients with CRC in the CpG island
of the PHD3 gene in regions chr14: 34 419 795–34
419 935 and chr14: 34 419 400–34 419 538 (p < 0.00001)
(Figure 3B; Table 2, Additional file 1, Additional file 2).
HRM results were compared with those obtained in bisul-
fite sequencing for all analyzed genes in reconstituted
samples. A similar pattern of DNA methylation was ob-
served between these two methods (Figure 3). Moreover,
we observed that an increase in the average DNA methyla-
tion level of PHD3 in regions chr14: 34 419 795–34 419
935 and chr14: 34 419 400–34 419 538 correlated to a de-
crease in the ratio of cancerous-to-histopathologically-
unchanged tissue PHD3 mRNA level (p < 0.0001) (Figure 4).
DNA methylation level of the PHD1, PHD2 and FIH genes
in HCT116 and DLD-1 CRC cells
To assess DNA methylation levels in the promoter re-
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Figure 3 DNA methylation assessment of PHD3 gene regulatory region by bisulfite sequencing and HRM analysis in primary tissue
samples from patients with CRC. Primary cancerous and histopathologically unchanged tissues from the same patients with CRC (P1-P5) were
used for genomic DNA isolation followed by bisulfite conversion of cytosine to uracil. The PHD3 regions containing 60 CpG dinucleotides (chr14:
34 419 929-34 420 563) (Top panel A) and 44 CpG dinucleotides (ch14: 34 419 346-34 419 943) (Top panel B) were then amplified by a pair
of primers complementary to the bisulfite-DNA modified sequence (Additional file 1, Additional file 2). The PCR products were purified with
subsequent cloning into a plasmid vector. Plasmid DNA isolated from five positive bacterial clones was used for commercial sequencing. The
results of bisulfite sequencing were assessed and presented using BiQ analyzer software and BDPC web server [23,24]. Black and grey boxes represent
methylated and unmethylated CpG dinucleotide, respectively. Red rectangles correspond to regions amplified in HRM analysis by specific primers
PHD3.1 (chr14: 34 419 922-34 420 080), PHD3.2 (chr14: 34 419 795- 34 419 935) and PHD3.3 (chr14: 34 419 400-34 419 538) (Additional file 1, Additional
file 2). Bottom panels A and B represent HRM profiles of standard and example of patient DNA (patient P2 from bisulfite sequencing) PCR product.
Methylation percentage of three DNA fragments within the PHD3 CpG island was determined by Real Time PCR amplification of bisulfite treated
standard and patient DNA, followed by comparison of their HRM profiles. DNA standards were prepared by mixing different ratios of methylated and
non-methylated bisulfite treated DNA. HRM methylation analysis was performed using Light Cycler®480 Gene Scanning software, Roche Diagnostics
GmbH (Mannheim, Germany). Each PCR amplification and HRM profile analysis was performed in triplicate.
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file 1, Additional file 2). We observed no DNA methyla-
tion of the promoter region of PHD1, PHD2 and FIH
gene in the analyzed regions using HRM analysis under
hypoxic and normoxic conditions (Additional file 6).
The hypermethylated PHD3 gene in HCT116 is not
induced upon hypoxia conditions
To evaluate the association between DNA methylation of
the PHD3 gene and its expression in HCT116 and DLD-1
CRC cell lines we performed HRM analysis, RQ-PCR,
and western blotting. We observed a high level of DNA
methylation in HCT116 and no DNA methylation inDLD-1 cells in the chr14: 34 419 922–34 420 080, chr14:
34 419 795–34 419 935 and chr14: 34 419 400–34 419
538 regions of PHD3 gene CpG island using HRM ana-
lysis in both hypoxic and normoxic conditions (Figure 5A).
We detected a lower level of PHD3 transcript and protein
in HCT116 cells compared to DLD-1 cells in both hypoxic
and normoxic conditions (Figure 5B, C). However, statis-
tical significance in these differences occurred only under
hypoxic conditions (Figure 5B, C). Moreover, we ob-
served a statistically significant induction of PHD3
transcript and protein level upon hypoxia in DLD-1
cells, with no changes in HCT116 cells under the same
conditions (Figure 5B, C).
Table 2 Methylation level of the regulatory region of the PHD3 gene in primary cancerous tissue and
histopathologically unchanged tissue sample from patients with CRC
Total no. of patients < 1% methylation 1–10% methylation 10–100% methylation pa
Histopathologically unchanged tissue 90 63 27 0 p < 0.00001
Primary cancerous tissue 37 31 22
The primary cancerous and histopathologically unchanged tissue samples from the same patients were used for genomic DNA isolation, followed by bisulfite
conversion of cytosine to uracil. The DNA fragments of the CpG island were then amplified by three pairs of primers complementary to the bisulfite-DNA modified
sequence (Additional file 1, Additional file 2). To determine the percentage of methylation, the HRM profiles of the patients’ DNA PCR products were compared to
HRM profiles of the prepared standard PCR products (Figure 3). DNA methylation of the PHD3 regulatory region for each patient was calculated as mean of the
percentage of methylation in two DNA amplified fragments where the differences between primary cancerous and histopathologically unchanged tissue where
observed. a Chi square test.
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region, PHD3 transcript and protein contents in HCT116
cells, and did not affect PHD3 DNA methylation or
expression levels in DLD-1 cells under hypoxic and nor-
moxic conditions
In order to assess the effect of 5-dAzaC on DNA methyla-
tion and PHD3 gene expression levels we used HRM
analysis, RQ-PCR, and western blotting. We observed no
effect of 5-dAzaC treatment on the DNA methylation sta-
tus in the analyzed regions of the PHD3 promoter region
in DLD-1 cells upon hypoxic and normoxic conditions
(Figure 6A, B, C). On the contrary, using HRM analysis
we noticed significant DNA demethylation in chr14: 34



















































Figure 4 Ratio of cancerous PHD3 mRNA level to histopathologically
methylation status: 0–1%; 1–10% and 10–100%. Methylation percentag
1, Additional file 2) was determined by Real Time PCR amplification of bisu
their HRM profiles. The methylation for each patient was calculated as an a
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methylation (Table 2) [28-30]. To evaluate the statistically significant differen
unchanged tissue PHD3 mRNA level between the three DNA methylation r
methylation), the non-parametric Kruskal-Wallis test was employed.chr14: 34 419 400–34 419 538 regions of the CpG island
of the PHD3 gene in HCT116 cells cultured for 48 hrs in
the presence of 5.00 μM 5-dAzaC in both hypoxic and
normoxic conditions (Figure 6A, B, C). The changes in
DNA methylation level were accompanied by 5-dAzaC
induced expression of PHD3 in HCT116 cells. We ob-
served that 5-dAzaC resulted in a progressive increase
in PHD3 transcript levels in HCT116 cells and no signifi-
cant changes for DLD-1 cells (Figure 7A). For HCT116
we found approximately a 2.45- and 2.59-fold significant
increase in PHD3 transcript levels at 48 hrs of incubation
under normoxic and hypoxic conditions, respectively
(Figure 7A). Alterations in PHD3 transcript levels in
HCT116 cells were associated with increased PHD3 protein Median 
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Figure 5 DNA methylation and expression level of the PHD3 gene in HCT116 and DLD-1 CRC cells. A. HCT116 and DLD-1 cells were
cultured under normoxic or hypoxic (1% O2) conditions for 48 hrs. Cells were then used for DNA isolation followed by bisulfite modification.
Methylation percentage of three DNA fragments within the PHD3 CpG island (Additional file 1, Additional file 2) in HCT116 and DLD-1 cells under
hypoxic and normoxic conditions was determined by Real Time PCR amplification of bisulfite treated standard and cell line DNA, followed by
comparison of their HRM profiles. B. Cells were cultured in DMEM either in hypoxic (1%O2) or normoxic conditions for 48 hrs. After incubation,
the cells were used for total RNA isolation and reverse transcription. The PHD3 cDNA levels were determined by RQ-PCR relative quantification
analysis. RQ-PCR results were standardized by the geometric mean of PBGD and hMRPL19 cDNA levels. PHD3 cDNA levels are expressed as a
multiplicity of these cDNA copies in the cell line’s calibrator. C. Cells were cultured in DMEM either in hypoxic (1%O2) (H) or normoxic
(N) conditions for 48 hrs. Cells were then used for protein isolation. Proteins were separated by 10% SDS-PAGE, and transferred to a membrane
that was then immunoblotted with Rp anti - PHD3 Ab and incubated with goat anti-rabbit HRP-conjugated Ab. The membrane was then stripped
and reblotted with Rp anti-GAPDH Ab, followed by incubation with goat anti-rabbit HRP-conjugated Ab. The band densitometry readings were
normalized to GAPDH loading control. The ratio of PHD3 to GAPDH for DLD-1 in normoxic conditions was assumed to be 1.
100%
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Figure 6 Effect of 5-dAzaC on PHD3 gene DNA methylation in HCT116 and DLD-1 CRC cells. HCT116 and DLD-1 cells were cultured under
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then used for DNA isolation followed by bisulfite modification. Methylation percentage of three DNA fragments within the PHD3 CpG island:
A (chr14: 34 419 922–34 420 080), B (chr14: 34 419 795–34 419 935) and C (chr14: 34 419 400–34 419 538) (Additional file 1, Additional file 2) in
HCT116 and DLD-1 cells under hypoxic and normoxic conditions was determined by Real Time PCR amplification of bisulfite treated standard
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Figure 7 5-dAzaC effect on PHD3 transcript (A) and protein (B) levels in HCT116 and DLD-1 CRC cells. HCT116 and DLD-1 cells were cul-
tured in DMEM for 6, 24 and 48 h either in the absence or in the presence of 5-dAzaC at a concentration of 1.00 or 5.00 μM under hypoxic or
normoxic conditions. After incubation the cells were used for total RNA isolation and protein isolation. Total RNA was reverse-transcribed, and
PHD3 cDNA levels were determined by RQ-PCR relative quantification analysis. RQ-PCR results were standardized by the geometric mean of PBGD
and hMRPL19 cDNA levels. PHD3 cDNA levels are expressed as a multiplicity of the respective controls. Each sample was determined in triplicate
and results are presented as the mean ± SE from three experiments *P < 0.05. The cell protein was separated by 10% SDS-PAGE, and transferred
to a membrane that was then immunoblotted with Rp anti - PHD3 Ab and incubated with goat anti-rabbit HRP-conjugated Ab. The membrane
was then stripped and reblotted with Rp anti-GAPDH Ab, followed by incubation with goat anti-rabbit HRP-conjugated Ab. The band densitom-
etry readings were normalized to GAPDH loading control. The ratio PHD3 to GAPDH for control was assumed to be 1.
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Densitometric analysis of western blotting bands indicated
an approximately 2.59- and 2.62- fold increase in PHD3
protein level in HCT116 cells incubated with 5.00 μM
5-dAzaC for 48 hrs as compared to the respective controls
under hypoxic and normoxic conditions, respectively. Incu-
bation of DLD-1 cells with 5-dAzaC at various concentra-
tions for different time periods did not significantly
increase PHD3 protein contents under either hypoxic or
normoxic conditions (Figure 7B).
Discussion
The maintenance of oxygen homeostasis is a crucial
physiological process [32]. Hypoxia is a common feature
of human cancers, associated with higher aggressiveness
and resistance to chemotherapy [33,34]. The cellular
environment response to hypoxia is mediated by HIF, a
heterodimeric transcriptional complex, which is post-
translationally regulated by prolyl and asparaginyl
hydroxylases. The first group, PHD enzymes, govern the
ubiquitin- mediated mechanism of HIF-α degradation
under normoxic conditions [3]. Since hydroxylation re-
actions require the presence of oxygen, dioxygenases are
unable to function in hypoxic conditions. Thus, the HIF
is not directed to proteasomal degradation and may
exert its effect on genes during CRC progression. How-
ever, oxygen concentration is not the only cause of altered
PHD function during tumorigenesis. The contribution of
PHD to cell behaviour depends on several conditions, in-
cluding the relative abundance of PHD proteins in a spe-
cific tissue [3]. Since changes in the amount of available
PHD enzymes will alter the rate of hydroxylation of
HIF-α, research has focused on the regulation of the quan-
tity of PHDs. Aberrant expression of PHDs has been
observed in a variety of human cancers. Detailed analysis
of the expression patterns of all three PHD isoforms has
shown differences depending on cancer cell type [7,35-37].
PHD1 protein levels were elevated in non-small cell
type lung cancer (NSCLC) and pancreatic endocrine
tumors [36,38]. Moreover, PHD1 inactivation resulted in
lower levels of Cyclin D1 and impaired breast tumour
formation [39]. However, it has been demonstrated that
colon cancer cells expressing the PHD1 gene causeinhibition of tumour growth and angiogenesis under
hypoxic conditions when injected into nude mice [40].
PHD2 was also previously studied in various cancer
types. Low levels of PHD2 expression were correlated
with poor survival rate in CRC and breast cancer [9,41].
Nonetheless, studies in head and neck squamous cell
carcinoma (HNSCC) demonstrated an association be-
tween increased levels of nuclear PHD2 protein with
strongly proliferative and malignant tumour phenotypes
[42,43]. Furthermore, immunohistochemical studies have
found that high PHD2 and PHD3 expression was signifi-
cantly associated with worse 5-year survival rate in pan-
creaticobiliary cancer [44]. PHD3 transcript levels were
shown to be increased in HNSCC, and in vitro analysis
revealed inhibition of cell cycle progression in cancerous
cells in the absence of PHD3 activity [45]. Elevated levels
of PHD3 protein in cancerous tissue were also observed
in immunohistochemical studies of NSCLC and gastric
cancer [38,46]. However, PHD3 catalytic activity has
demonstrated an ability to induce apoptosis independent
of HIF in different cancer cell lines [12,47-49]. Addition-
ally, Peurala et al. presented that increased PHD3 ex-
pression and was associated with an increased survival
rate in breast cancer patients [41].
Discrepancies between PHD1, PHD2 and PHD3 ex-
perimental results might be partly explained by the dem-
onstration that HIF and PHDs can form a feedback loop
that limits hypoxic signaling in reoxygenated cells [50].
Moreover, these discrepancies imply a dual function of
PHDs in the control of tumour progression that depends
on cell type, other PHDs- interacting factors, and func-
tion independent of HIF. The HIF- independent func-
tions of PHDs include PHD3 directed inhibition of
phosphorylation of the inhibitor of κβ kinase β and acti-
vation of NF κβ in CRC, neuronal apoptosis and myo-
blast differentiation by PHD3, or control of myocardial
development by PHD2 [8,51,52].
We found a statistically significant decrease in the
expression levels of the PHD1, PHD2 and PHD3 genes
in cancerous tissue compared to histopathologically un-
changed colorectal tissue. Although we did not observe
statistically significant differences in FIH transcript levels
between cancerous and histopathologically unchanged
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protein in CRC. FIH, in addition to PHDs, hydroxylates
HIF-α at a conserved asparagine residue. Through this
modification, FIH prevents interaction of HIF with its
transcriptional coactivators [5]. More importantly, FIH is
able to suppress HIF activity under severe hypoxic con-
ditions, where PHDs are inactive [53,54]. Additionally,
FIH exerts HIF-independent functions by interaction
with pVHL, histone deacetylases, p105, Notch 1, and
SOCS box proteins [55-58]. FIH is widely expressed;
however, its expression varies between tissue and cancer
types [7]. To date, FIH protein overexpression was cor-
related with a more malignant phenotype and poor
prognosis in pancreatic endocrine tumours and NSCLC,
respectively [36,38]. Moreover, it has been established
that FIH gene silencing reduced colon cancer cell prolif-
eration in vitro and in vivo through the p53-p21 medi-
ated pathway [54]. We observed a significant increase in
the protein level of FIH in CRC tissue. This observation
may result from E3 ligase activity of a member of seven
in absentia homolog 1 (SIAH-1). Therefore, SIAH-1
facilitates ubiquitination and proteasomal degradation of
FIH [59,60]. To date, SIAH-1 has been found to be
widely distributed in human cell lines and tissues, in-
cluding CRC, with a decreased expression in breast and
hepatocellular cancer [61-63].
Since the prolyl and asparaginyl hydroxylases have so
wide and profound an effect on tumorigenesis, studies
on the regulation of the expression of these enzymes
may help in our understanding of CRC progression.
There are many factors involved in the development and
occurrence of CRC, and they are classified as genetic,
epigenetic and environmental [64-67]. One of the epi-
genetic mechanisms, namely altered DNA methylation
in a gene’s regulatory region, is observed from the early
stages of lesions in aberrant crypt foci and hyperplastic
polyps [68,69]. It has been shown that DNA hyperme-
thylation of MLH1, MGMT, CDKN2A and many others
is associated with CRC progression [67,70-72]. Our
study is the first to investigate the methylation status of
the promoter regulatory regions of PHD1, PHD2, PHD3
and FIH in primary cancerous tissue from patients with
CRC, and HCT116, DLD-1 CRC cell lines. We did not
observe DNA methylation within the CpG island of the
PHD1, PHD2 and FIH gene promoter in either patients
or cell lines. To date, the DNA methylation status of
the promoter region of PHD1, PHD2, PHD3 and FIH
was studied in a few cancers, including breast, prostate,
cervical, melanoma, kidney and plasma cell neoplasia
[12-15]. In cervical cancer cell lines the hypomethylation
of the CpG island of the PHD2 gene promoter was asso-
ciated with an increase in PHD2 expression [15]. Simi-
larly to our results, no DNA methylation within the
CpG island of PHD1, PHD2 and FIH has been observedin breast and plasma cell neoplasia [13,14]. There was
also no DNA methylation in the promoter region of the
PHD3 gene in clinical samples from breast and prostate
cancer [12,14]. We also observed no DNA methylation
within the PHD3 gene using bisulfite sequencing in re-
gion chr14: 34 419 929–34 420 563 and HRM analysis
in region chr14: 34 419 922–34 420 080 in a group of
patients, which is consistent with the results of Huang
et al. and Place et al. [12,14]. However, we found a
significantly higher level of DNA methylation within the
first exon and intron of the PHD3 gene (chr14: 34 419
346–34 419 943 using bisulfite sequencing; chr14: 34
419 795–34 419 935 and chr14: 34 419 400–34 419 538
using HRM analysis) in cancerous tissue compared to
histopathologically unchanged tissue. To the best of our
knowledge, DNA methylation within the chr14: 34 419
346–34 419 943, chr14: 34 419 795–34 419 935 and
chr14: 34 419 400–34 419 538 regions was not previ-
ously analyzed in other studies. Data from Encyclopedia
of DNA elements project showed that these regions are
DNase I hypersensitive and able to bind various tran-
scription factors, which suggests a promoter or enhancer
activity [22]. Moreover, Pescador et al. (2005) identified
a functional HRE within the first intron of the PHD3
gene and proposed a model of HIF-mediated hypoxic
induction of PHD3 [73].
Since hypoxic conditions may induce global DNA hypo-
methylation in cancer cells, we investigated DNA methyla-
tion and expression levels of the PHD3 gene in HCT116
and DLD-1 cells under hypoxic and normoxic conditions
[74]. We reported a high level of DNA methylation and
no transcript and protein level changes under hypoxic
and normoxic conditions in HCT116 cells. In the PHD3
gene promoter region in DLD-1 cells, we did not detect
DNA methylation under either experimental condition,
but we observed a significant induction of PHD3 tran-
script and protein level upon hypoxia. The PHD3 gene
possesses in its promoter region a putative HRE and can
be induced by HIF transcription factor complex under
hypoxic conditions [35]. A lack of increase in PHD3
expression in HCT116 cells might be the result of DNA
methylation of its promoter region in hypoxic conditions.
To date, a decreased expression of PHD3 mRNA was cor-
related with high CpG island methylation status in plasma
cell neoplasia and selected melanoma, prostate and mam-
mary gland cancer cell lines [12,13].
In order to verify the role of DNA methylation within
the CpG island of the PHD3 gene, we treated HCT116
and DLD-1 cells with 5-dAzaC under normoxic and
hypoxic conditions. 5-dAzaC was previously shown to
induce the expression of many genes in different types
of cancer and inhibit the growth of CRC cells [75,76].
We observed significant DNA demethylation in the
chr14: 34 419 922–34 420 080, chr14: 34 419 795–34
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the CpG island of the PHD3 gene in HCT116 cells incu-
bated with 5-dAzaC, which was correlated with an in-
crease in PHD3 transcript and protein levels. The same
regions were unmethylated in DLD-1 cells at different
experimental conditions and 5-dAzaC did not affect
PHD3 gene expression.
The presence of DNA hypermethylation of the PHD3
promoter region in a broad range of human cancers sug-
gests its role in tumour survival. In glioblastoma cell
lines, accumulation of PHD3 protected tumour cells
against hypoxia-induced cell death via control of HIF
[77]. However, reduction of PHD3 expression by DNA
methylation may allow for stable HIF directed cellular
response during hypoxia [12]. Moreover, in a subset of
breast, prostate, melanoma and renal carcinoma cell
lines, HIF-1α accumulation during hypoxia was inde-
pendent of DNA hypermethylation of the PHD3 pro-
moter region, which suggests its role in other pathways
and hydroxylase independent function [12].
Conclusion
Our results showed increased DNA methylation levels in
the CpG island of PHD3 in CRC as compared to normal
colonic epithelium from the same patients. These epigen-
etic alterations were associated with a significant decrease
of PHD3 expression levels in patients with CRC. How-
ever, the reduction in PHD1 and PHD2 expression in
cancerous tissue was not due to altered methylation
within the CpG island in the promoter region of PHD1
and PHD2, respectively. Therefore, other mechanisms
might be responsible for the observed decreased ex-
pression levels of PHD1 and PHD2 in CRC patients.
Furthermore, we observed an increased level of FIH pro-
tein in CRC, with no changes in the FIH transcript level
between cancerous and histopathologically unchanged co-
lonic mucosa. Additionally, we observed different statis-
tical values of transcript and protein levels of the analyzed
genes for subgroups of patients classified according to
different features. However, a larger group of patient and
deeper molecular investigation of these observations
should be studied to determine whether the results within
subgroups may be clinically important.
We also found that an inhibitor of DNMTs, 5-dAzaC,
induced DNA demethylation of the PHD3 promoter re-
gion, which was associated with increased transcript and
protein levels in HCT116 cells under hypoxic and nor-
moxic conditions.
Although we presented epigenetic transcriptional down-
regulation of PHD3 gene expression in CRC patients and
HCT116 CRC cell line for the first time, further studies
are required to verify and determine the role of CpG is-
land methylation in PHD3 expression in CRC to a greater
extent. Moreover, DNA methylation is often associatedwith other alterations in chromatin structure, namely his-
tone acetylation. High levels of DNA methylation accom-
panied with a low degree of histone acetylation may
decrease the transcription of many genes [78]. In
consideration of this, we also need to determine the
possible role of histone modifications in PHD3 gene
expression.
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